Pearl Cohen represents Orgenesis, Inc. in its Reorganization of Its Israel and Korea Subsidiaries
Orgenesis Inc. (NASDAQ: ORGS), a leading cell and gene therapy enabling company, providing centralized CDMO manufacturing and development services through its subsidiary MTH Global, Inc., as well as localized point-of-care development and processing centers, today announces that it has transferred the ownership of its Israeli cell process development business, Atvio Biotech Ltd., and its South Korean cell development and manufacturing business, CureCell Co., Ltd. from its subsidiary, Masthercell Global, to the parent company, Orgenesis, Inc. Atvio and Curecell will provide internal manufacturing services to Orgenesis, and to customers located within Israel and South Korea, respectively.
The Pearl Cohen team was led by Mark Cohen, Senior Partner and Chair of the Life Science Practice Group, Benjamin Waltuch, Partner, Darie Ofek, Partner, Yitzchak Chamudot, Partner, Oz Halabi, Partner, and Elina Pevzner, Associate.
